Clinical Trial Update: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is testing whether rituximab reduces glucocorticoid exposure in polymyalgia rheumatica patients experiencing relapse; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Sint Maartenskliniek | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: ACTIVE_NOT_RECRUITING